ABSTRACT OF DISCLOSURE

Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant 5 liability of adverse side-effects associated with other non-sedating antihistamines.